Compile Data Set for Download or QSAR
Report error Found 256 Enz. Inhib. hit(s) with Target = 'Mitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085]'
TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415402(US10428063, Example 2 | Intermediate 1-1-2)
Affinity DataIC50: 7.89nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415417(US10428063, Example 17 | Intermediate 1-2-9)
Affinity DataIC50: 8.70nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415431(US10428063, Example 31 | 2-[3-(2-methoxyethoxy)pyr...)
Affinity DataIC50: 9.93nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415406(US10428063, Example 6 | Intermediate 1-1-3)
Affinity DataIC50: 10.9nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415418(US10428063, Example 18 | Example 18 (2-(3-fluoropy...)
Affinity DataIC50: 11.5nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415401(US10428063, Example 1 | Intermediate 1-1-1 (4-hydr...)
Affinity DataIC50: 11.6nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415420(US10428063, Example 20 | Intermediate 1-1-5)
Affinity DataIC50: 13.4nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415404(US10428063, Example 4 | Example 4 (1-ethyl-6,6-dim...)
Affinity DataIC50: 14.6nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415424(US10428063, Example 24 | N-{4-[5-methyl-4-oxo-3-(p...)
Affinity DataIC50: 15.3nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415412(US10428063, Example 12 | Intermediate 1-2-7)
Affinity DataIC50: 15.4nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415425(US10428063, Example 25 | US10428063, Example 40 | ...)
Affinity DataIC50: 17.1nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415414(US10428063, Example 14 | Example 14 (N-{4-[4-oxo-3...)
Affinity DataIC50: 18.3nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415416(US10428063, Example 16 | Intermediate 1-2-8)
Affinity DataIC50: 19.1nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415447(US10428063, Example 47 | 3-[(3-fluorophenyl)amino]...)
Affinity DataIC50: 19.4nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415419(US10428063, Example 19 | Example 19 (1-ethyl-3-{4-...)
Affinity DataIC50: 19.5nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415407(US10428063, Example 7 | Intermediate 1-1-4)
Affinity DataIC50: 19.8nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415427(US10428063, Example 27 | 2-[3-(cyclopropylmethoxy)...)
Affinity DataIC50: 21.7nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415434(US10428063, Example 34 | 5-methyl-3-(phenylamino)-...)
Affinity DataIC50: 22.5nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415423(US10428063, Example 23 | N-{4-[5-methyl-4-oxo-3-(p...)
Affinity DataIC50: 23.2nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415439(US10428063, Example 39 | 2-[3-(cyclopropylmethoxy)...)
Affinity DataIC50: 24.1nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415422(US10428063, Example 22 | 2-(3-methoxypyridin-4-yl)...)
Affinity DataIC50: 26.9nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415445(US10428063, Example 45 | 3-[(3,4-difluorophenyl)am...)
Affinity DataIC50: 28nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415425(US10428063, Example 25 | US10428063, Example 40 | ...)
Affinity DataIC50: 28.1nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415446(US10428063, Example 46 | 3-[(4-fluorophenyl)amino]...)
Affinity DataIC50: 32.8nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415436(US10428063, Example 36 | 2-(3H-imidazo[4,5-b]pyrid...)
Affinity DataIC50: 34.8nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415405(US10428063, Example 5 | Example 5 (1-ethyl-3-(phen...)
Affinity DataIC50: 35.1nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415441(US10428063, Example 41 | 2-[3-(2,2-difluoroethoxy)...)
Affinity DataIC50: 36.8nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415432(US10428063, Example 32 | 2-[3-(benzyloxy)pyridin-4...)
Affinity DataIC50: 41.6nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415426(US10428063, Example 26 | 2-[3-(2-hydroxyethoxy)pyr...)
Affinity DataIC50: 47.6nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415428(US10428063, Example 28 | 5-methyl-3-(phenylamino)-...)
Affinity DataIC50: 51.6nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415433(US10428063, Example 33 | 5-methyl-3-(phenylamino)-...)
Affinity DataIC50: 51.8nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415438(US10428063, Example 38 | 2-[3-(cyclopropylmethoxy)...)
Affinity DataIC50: 56.1nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415437(US10428063, Example 37 | 2-[3-(cyclopropylmethoxy)...)
Affinity DataIC50: 59.8nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415411(US10428063, Example 11 | Example 11 (1-ethyl-3-[(4...)
Affinity DataIC50: 64.5nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415444(US10428063, Example 44 | 2-{3-[2-(dimethylamino)et...)
Affinity DataIC50: 69.9nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415429(US10428063, Example 29 | 2-[3-(2,2-difluoroethoxy)...)
Affinity DataIC50: 70.8nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415415(US10428063, Example 15 | Example 15 (N-{4-[1-ethyl...)
Affinity DataIC50: 79nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415430(US10428063, Example 30 | 5-methyl-3-(phenylamino)-...)
Affinity DataIC50: 84.3nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415435(US10428063, Example 35 | 2-[3-(3,3-dimethylbutoxy)...)
Affinity DataIC50: 85.9nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415442(US10428063, Example 42 | 2-[3-(2,2-difluoroethoxy)...)
Affinity DataIC50: 111nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415443(US10428063, Example 43 | 2-[3-(2,2-difluoroethoxy)...)
Affinity DataIC50: 136nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415408(US10428063, Example 8 | Intermediate 1-2-6)
Affinity DataIC50: 138nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415421(US10428063, Example 21 | Intermediate 1-2-11)
Affinity DataIC50: 170nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM162190(US9682995, 89)
Affinity DataIC50: 210nMpH: 8.0Assay Description:Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose aff...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415403(US10428063, Example 3 | Intermediate 1-2-3)
Affinity DataIC50: 244nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415410(US10428063, Example 10 | (2-methyl-N-{4-[5-(2-meth...)
Affinity DataIC50: 319nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415409(US10428063, Example 9 | Example 9 (1-(2-methoxyeth...)
Affinity DataIC50: 354nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415413(US10428063, Example 13 | Example 13 (1-ethyl-2-(2-...)
Affinity DataIC50: 972nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM696443((+)-3-(3-chloro-2-methoxyanilino)-2-{3-[2-(oxetan-...)
Affinity DataIC50: 1.08E+3nMAssay Description:For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a black low volume 384 well microtiter ...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1 [704-1085](Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM696444((−)-3-(3-chloro-2-methoxyanilino)-2-{3-[2-(o...)
Affinity DataIC50: 1.54E+3nMAssay Description:For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a black low volume 384 well microtiter ...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 256 total ) | Next | Last >>
Jump to: